Scott Weir, PharmD, PhD
Associate Director, Translational Research - Drug Discovery
Co-Leader, Drug Discovery, Delivery & Experimental Therapeutics (D3ET)
Director, Institute For Advancing Medical Innovation, The University of Kansas Medical Center
Frank B. Tyler Cancer Research Professor in Therapeutic Discovery
Professor, Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas School of Medicine
Dr. Weir brings more than 25 years of drug development experience to lead the D3ET Research Program. His leadership, experience and partnerships with the pharmaceutical industry, other academic institutions, government and disease philanthropy organizations are paving the way for The University of Kansas Cancer Center to attain its goal of being one of the top academic institutions advancing new drug therapies from the bench to the bedside. Dr. Weir joined the University of Kansas Cancer Center in February 2006 to establish and manage a fully integrated drug discovery and development program.
In addition to his cancer center responsibilities, Dr. Weir directs The Institute for Advancing Medical Innovation (IAMI). The institute is rapidly establishing a national reputation as one of the most innovative academic proof-of-concept centers. IAMI has supported the advancement of several new drug therapies to clinical trials. He also serves on advisory boards for Orbis Pharmaceuticals Inc and The Institute for Pediatric Innovation. Additionally, he serves on the steering committee for the Heartland Institute for Clinical and Translational Research as well as the Advisory Committee on Science, Technology, and the Future, a committee assembled by US Senator Pat Roberts. In 2010, Kansas Bio named Weir “A Kansas Big Thinker."
Dr. Weir received his PharmD degree in 1980 from the University of Nebraska College of Pharmacy, followed by a PhD in pharmacokinetics and biopharmaceutics from the University of Nebraska Medical Center in 1986.
He joined Marion Laboratories, Inc. in 1986 as a clinical pharmacokineticist. From 1988 through 1998, he assumed a series of management positions with increasing responsibility at Marion Laboratories, Inc., Marion Merrell Dow, Inc. Hoechst Marion Roussel, Inc., and Aventis Pharmaceuticals, Inc. Dr. Weir was actively involved with R&D reengineering efforts for each of these companies in 1992 and 1997. He was directly involved in the successful registration of Cardizem CD, Cardizem Injectable, Anzemet Tablets, Anzemet Injectable, Pentasa, Carafate, Rifater and Allegra, and led the global integration and harmonization activities for drug metabolism and pharmacokinetics during the early stages of the Hoechst Marion Roussel Inc. merger.
From 1999 through early 2006, Dr. Weir led early drug development divisions within Quintiles Inc. and Aptuit Inc. Dr. Weir’s specific areas of expertise and research interest are in clinical pharmacology and developing innovative approaches in lead optimization and early drug development.